Modus Therapeutics pauses enrollment in Phase IIa sevuparin trial after serious adverse event

• Modus Therapeutics voluntarily paused enrollment in Part 2 of its Phase IIa sevuparin trial for chronic kidney disease with anemia.
• A serious adverse event prompted the precautionary pause; a causal link to sevuparin has not been established.
• The pause was not regulator-imposed; no ongoing patient treatment required discontinuation.
• Proof-of-concept results are now expected in the first quarter of 2027, versus around the turn of 2026/2027 previously.
• Cash is expected to fund operations into the second quarter of 2027; an updated financing assessment is due November 24, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modus Therapeutics Holding AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.